Versartis Hires Cowen to Assist in Evaluating Potential Strategic Transactions
26 Octobre 2017 - 10:05PM
Versartis, Inc. (NASDAQ:VSAR), an endocrine-focused
biopharmaceutical company, today announced that it has retained
Cowen to assist in evaluating possible strategic transactions. The
process is aimed at identifying opportunities to diversify the
Versartis pipeline, including through potential strategic
combinations, in order to leverage the company’s expertise and
resources and create value for shareholders.
No assurances can be made as to whether a strategic transaction
will be recommended by the Board of Directors, and Versartis does
not intend to discuss developments with respect to the evaluation
process unless a transaction is approved or disclosure becomes
appropriate.
Contacts:
Joshua BrummCOO & CFO (650) 963-8582jbrumm@versartis.com
VERSARTIS, INC. (NASDAQ:VSAR)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
VERSARTIS, INC. (NASDAQ:VSAR)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Aravive (delisted) (NASDAQ): 0 recent articles
Plus d'articles sur